ReviewCurrent oncology reports2016
Evolving Immunotherapy Approaches for Renal Cell Carcinoma.
Review in Current oncology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Time-dynamic considerations in second primary cancers after renal cell carcinoma: a comment on Tundealao et al.International urology and nephrology · 2026Article
- Mechanisms and Therapeutic Strategies to Overcome Immune Checkpoint Inhibitor Resistance in Melanoma, Head and Neck, and Triple-Negative Breast Cancers.Journal of cellular immunology · 2025Article
- Cuproptosis related gene PDHB is identified as a biomarker inversely associated with the progression of clear cell renal cell carcinoma.BMC cancer · 2023Article
- Prognostic prediction of clear cell renal cell carcinoma based on lipid metabolism-related lncRNA risk coefficient model.Frontiers in genetics · 2022Article
- Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development.Frontiers in immunology · 2022Article
- Downregulation of FXYD2 Is Associated with Poor Prognosis and Increased Regulatory T Cell Infiltration in Clear Cell Renal Cell Carcinoma.Journal of immunology research · 2022Article
- Suppressive effects of RASAL2 on renal cell carcinoma via SOX2/ERK/p38 MAPK pathway.Experimental and therapeutic medicine · 2020Article
- Memory stem T cells generated by Wnt signaling from blood of human renal clear cell carcinoma patients.Cancer biology & medicine · 2019Article
- Immunotherapy for Brain Tumors.Current treatment options in oncology · 2018Review
- Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis.Vaccines · 2018Review
- Molecular Characterization and Putative Pathogenic Pathways of Tuberous Sclerosis Complex-Associated Renal Cell Carcinoma.Translational oncology · 2018Article
- Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties.Scientific reports · 2017Article
- Reduced E-cadherin facilitates renal cell carcinoma progression by WNT/β-catenin signaling activation.Oncotarget · 2017Article
- Intraperitoneal immunotherapy: historical perspectives and modern therapy.Cancer gene therapy · 2016Review
- Outcomes of Laparoscopic Nephron-Sparing Surgery versus Radical Nephrectomy in Renal Cell Carcinoma.JSLS : Journal of the Society of Laparoendoscopic SurgeonsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic renal cell carcinoma (mRCC) continues to be associated with high rates of morbidity and mortality. Renal cell carcinoma (RCC) is typically resistant to cytotoxic chemotherapy, and while targeted therapies have activity and prolong progression-free and overall survival, responses are usually not durable. Modulating the immune system with cytokine therapy, vaccine therapy, cell therapy, and checkpoint inhibitors offers hope of prolonged survival. Standard and emerging immune therapy approaches and combinations of immune therapies and other modalities are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.